Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock
April 15, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
March 17, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes
March 10, 2021 00:20 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization...
Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes
March 08, 2021 17:01 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization...
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments
March 08, 2021 16:05 ET
|
Avid Bioservices, Inc
-- Third Quarter Revenue Increased 61% to $21.8 Million -- -- Signed $74 Million in New Orders to End the Quarter with a Backlog of $120 Million -- -- First Phase of Myford Expansion on Target,...
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
March 03, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021
March 01, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan
February 22, 2021 08:05 ET
|
Avid Bioservices, Inc
Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites Phase 2 Has Potential to Increase Annual Revenue...
Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
February 03, 2021 07:00 ET
|
Avid Bioservices, Inc
BURLINGAME, Calif. and TUSTIN, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced...
Avid Bioservices Announces Closing of Public Offering of Common Stock
December 14, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...